June 24, 2021 – TRON uses GSI/FAIR experiment period for cancer research: combination of heavy ion therapy and mRNA vaccine It is a strong alliance for research in the fight against cancer, opening the way for exciting new developments. On one hand, the GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt with its worldwide unique accelerator facilities
Author Archive | thomas
We are very proud to have been selected for the concept phase of the “Clusters4Future” initiative of the Federal Ministry of Education and Research (BMBF). Among this year’s 15 finalists is the cluster concept “curATime – Cluster for Atherothrombosis and Individualized Medicine”, which was developed in collaboration between TRON gGmbH, the Center for Thrombosis and
Unsere herzlichen Glückwünsche: TRON-Gründer Ugur Sahin und Özlem Türeci erhalten das Bundesverdienstkreuz für die kurzfristige Entwicklung und Zulassung eines Impfstoffes gegen Covid-19 mit ihrem Unternehmen BioNTech, wie das Bundespräsidialamt mitteilte. Türeci und Sahin hätten durch ihren “unermüdlichen Einsatz” einen “entscheidenden Beitrag zur Eindämmung der Corona-Pandemie geleistet”. Die Verleihung des höchsten deutschen Verdienstordens an das Unternehmerpaar
In this recent study published in European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI), researchers from TRON, JGU Medical Center and BioNTech employed an in vitro transcribed mRNA encoding for sodium iodide symporter (NIS) to efficiently visualize and quantify the biodistribution of NIS RNA-lipoplex nanoparticles targeted to spleen or lung. Tissues expressing the RNA-encoded
Within the last year, a few infections with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) quickly turned into the global COVID-19 pandemic infecting and threatening death for millions of people all over the globe. The viral spike protein is responsible for viral binding and entry to host cells and thus mediates infection. Hence, the protein
Congratulations! TRON researcher Fulvia Vascotto was part of the team around Annette B. Vogel and Ugur Sahin, publishing pre-clinical results in Nature. The study supported the rapid development of BioNTech/Pfizer´s vaccine COMIRNATY (BNT162b2), the now globally deployed mRNA based vaccine against Covid-19. The recently published paper displays immune response data of two vaccine candidates (BNT162b1
Dr. Özlem Türeci and Prof. Dr. Ugur Sahin have been awarded the Academy Prize of the State of Rhineland-Palatinate for innovative and forward-looking research for their extraordinary achievements leading to the development of a vaccine against the Corona virus. On behalf of all TRON employees, we warmly congratulate Dr. Özlem Türeci and Professor Ugur Sahin,
Loss of immunological self-tolerance followed by attack of self-reactive T cells to target organs plays a major role in the formation of autoimmune diseases such as multiple sclerosis (MS). In a very recent study published in Science, our researchers (in collaboration with Johannes Gutenberg University Medical Center and BioNTech) employed a non-inflammatory RNA vaccine that
The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome
TRON is delighted to announce the publication of a scientific article in OncoImmunology.
TRON is proud to join the Cancer Research Institute this June 12 in bringing global awareness about the life-saving potential of cancer immunotherapy. By wearing white together, we are driving the future of immune-based science and medicine for cancer treatments, and ultimately, cures. Learn more about TRON’s mission and work at www.tron-mainz.de.
TRON is delighted to announce a scientific article published in Oncotarget.